Multi-Center Clean Air Randomized Controlled Trial in COPD
Who can join
As published by the study on ClinicalTrials.gov. "Not stated" means the study hasn't said — ask the study team.
- Age
- 40 Years and older
- Sex
- All sexes
- Healthy volunteers
- Not accepted
- Compensation
- Not stated
Other requirements are listed under Eligibility below. Only the study team can confirm whether you can join.
What to expect
No one can promise a trial will help you personally — that is what the research is trying to find out.
What participation involves
- Time periods mentioned: 1 year
Only what the study's summary and detailed description on ClinicalTrials.gov say. Time periods may describe the whole study or a part of it — ask the study team what applies to you.
Show the study's own words
- "The Multi-Center Clean Air Randomized Controlled Trial in COPD (Clean Air) is a multi-center, prospective, randomized, double-blind, sham-controlled trial that will enroll 770 former smokers with COPD over a 4-year period and follow participants at regular intervals for one year."
- Compensation
- Not stated
- Study-related exams and procedures are typically provided at no cost. This is how many trials work in general — confirm the details for this study with the study team.
- Participants are monitored closely by the research team throughout the study.
- Some participants may receive access to an investigational treatment, which is still being studied.
- Your participation helps researchers learn whether this approach could help future patients.
About this study
In plain language
This study tests whether home air cleaners can reduce flare-ups of COPD, a long-term lung disease. It also looks at quality of life, ability to do daily activities, and use of quick-relief medicines. It is for adults age 40 or older with COPD who have stopped smoking cigarettes.
This is a multi-center randomized, sham-controlled clinical trial to determine the effectiveness of an air cleaner intervention aimed at improving indoor air quality on reducing COPD exacerbation risk and improving quality of life, functional status, rescue medication use.
Compensation is read from the study's own description and may be missing — always confirm with the study team.
Eligibility
Who can join
- You are age 40 or older.
- You report that a doctor diagnosed you with COPD.
- A breathing test after medicine to open your airways confirms blocked airflow, with an FEV1/FVC ratio below 0.7.
- You have smoked cigarettes for at least 10 pack-years, such as 1 pack a day for 10 years.
- You report quitting cigarettes at least 6 months ago. E-cigarette use does not count toward this rule.
- You meet at least one of these: a COPD symptom score (CAT) of 10 or higher; a breathlessness score (mMRC) of 2 or higher; or a flare-up in the past 12 months that needed steroid medicine, antibiotics, an emergency room visit, or a hospital stay.
Who can't join
- You live somewhere other than a home, such as a nursing home or long-term care center.
- You have another long-term lung disease besides COPD. Asthma is allowed.
- You have a condition expected to limit your life to less than 1 year, or you are in hospice care.
- You spend more than 2 months a year away from home, or plan to move in the next 12 months.
- You are pregnant or breastfeeding.
- You use an air cleaner at home and are not willing to stop using it.
- You cannot bring air cleaners weighing about 15 pounds each into your home, even with help from a friend or relative.
- The study doctor thinks you cannot complete the study, including because you may lack internet access, or you are in another trial that tests a treatment or other health intervention.
Simplified for readability. The official criteria below are what the study team uses.
Official eligibility criteria
Inclusion criteria To be eligible, subjects must meet all these criteria: 1. Age ≥ 40 years. 2. Self-report of physician diagnosis of COPD. 3. Spirometry confirmed airway obstruction (post-bronchodilator spirometry of forced expiratory volume in 1 second (FEV1)/forced vital capacity (FVC) \< 0.7) as defined by the Global Initiative for Obstructive Lung Disease (GOLD) criteria (6, 11) 4. Tobacco exposure ≥ 10 pack-years. This refers to regular cigarette tobacco consumption. 5. Self-reported former smoker of at least 6 months' duration. This does not include e-cigarette use. 6. COPD Assessment Test (CAT) score ≥ 10, Modified Medical Research Council dyspnea scale (mMRC) ≥ 2, or history of moderate or severe exacerbation in the past 12 months (as defined by history of receiving a course of systemic corticosteroids or antibiotics for respiratory problems; or visiting an emergency department or being hospitalized for a COPD exacerbation within the past 12 months.) Exclusion criteria To be eligible, subjects must not meet any one of these criteria: 1. Living in a location other than home (e.g., long-term care facility, nursing home) 2. Other chronic lung diseases, except asthma 3. Condition with less than a year of life expectancy (e.g., metastatic cancer) or in hospice 4. Spends \>2 months per year in location other than home; or plans to change residence in the next 12 months 5. Pregnant or breastfeeding 6. Current air cleaner use in the home (\*If the individual is willing to discontinue use of the personal air cleaner, this person can be eligible if all other eligibility has been met) 7. Inability to bring air cleaners (about 15 pounds each) into home, either by self, friend, or relative 8. Deemed by the study investigator to be unable to complete study protocol, including likely lack of internet connectivity 9. Participating in another interventional clinical trial
Study sites (11)
AL
- University of Alabama, Lung Health Center · Birmingham, AL 35233Geneva Avery · Study contact · 205-934-5555 · lunghealth@uabmc.eduJames Michael Wells, MD · Principal investigatorMore trials in Birmingham
CA
- University of California, Los Angeles · Los Angeles, CA 90095Tiffany Bina · Study contact · 310-206-1629 · tbina@mednet.ucla.eduIgor Barjaktarevic, MD · Principal investigatorMore trials in Los Angeles
IA
- University of Iowa · Iowa City, IA 52242Eric Garcia · Study contact · 319-353-8863 · eric-garcia@uiowa.eduAlejandro Comellas, MD · Principal investigatorMore trials in Iowa City
MA
- Beth Israel Deaconess Medical Center · Boston, MA 02215Alethea atadika · Study contact · 781-964-8163 · aatadika@bidmc.harvard.eduMary Rice, MD · Principal investigatorMore trials in Boston
MD
- University of Maryland · Baltimore, MD 21201Valeriya Rodionova · Study contact · 410-328-2835 · vrodionova@som.umaryland.eduWilliam Grier, MD · Principal investigatorMore trials in Baltimore
- Johns Hopkins · Baltimore, MD 21224Wendy Lorizio · Study contact · 410-510-2449 · wlorizi1@jhmi.eduMaggie Maly · Study contact · 410-550-9527 · mmaly1@jhmi.eduMore trials in Baltimore
- Tidal Health · Salisbury, MD 21801Sandra Fetko · Study contact · 410-912-6045 · sandra.fetko@tidalhealth.orgRobert Chasse, MD · Principal investigatorMore trials in Salisbury
MI
- University of Michigan · Ann Arbor, MI 48109Crystal Cutlip · Study contact · 734-647-6399 · ccutlip@med.umich.eduMeilan Han, MD · Principal investigatorMore trials in Ann Arbor
NH
- Dartmouth Hitchcock · Lebanon, NH 03756Athena Fowler · Study contact · 603-650-0567 · athena.r.fowler.shaw@hitchcock.orgLaura Paulin, MD · Principal investigatorMore trials in Lebanon
OH
- Cleveland Clinic · Cleveland, OH 44195Elena Engel · Study contact · 224-235-8363 · engele2@ccf.orgRussel Bowler, MD · Principal investigatorMore trials in Cleveland
PA
- Reading Hospital · West Reading, PA 19611Pamela marrero · Study contact · 484-628-8355 · pamela.marrero@towerhealth.orgLuis Murillo, MD · Principal investigatorMore trials in West Reading